Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.（NVCT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · NVCT · 截至 2026年6月8日
活动摘要
买入笔数
25
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Nuvectis Pharma, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
NVCT 季度内部人买卖趋势
NVCT 内幕交易卖出 · NVCT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · NVCT CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
NVCT 高管卖出股份 · NVCT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jan 6, 2026 | Shemesh Shay Chief Dev. & Ops. Officer | Award | 150,000 | — | Form 4 |
| Jan 6, 2026 | BENTSUR RON Chairman & CEO · Director | Award | 150,000 | — | Form 4 |
| Jan 6, 2026 | Poradosu Enrique Chief Science & Business Off | Award | 150,000 | — | Form 4 |
| Jan 6, 2026 | Carson Michael J. Vice President, Finance | Award | 61,200 | — | Form 4 |
| Nov 5, 2025 | BENTSUR RON Chairman & CEO · Director | Purchase | 5,000 | $29K | Form 4 |
| Nov 5, 2025 | Sanchez Juan Director | Purchase | 13,000 | $75K | Form 4 |
| Nov 5, 2025 | Kaplan Matthew L. Director | Purchase | 11,000 | $64K | Form 4 |
| Sep 22, 2025 | Sanchez Juan Director | Award | 30,000 | — | Form 4 |
| Oct 27, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 72,836 | $457K | Form 4 |
| Oct 24, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 35,034 | $215K | Form 4 |
| Oct 23, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 46,900 | $284K | Form 4 |
| Jun 20, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 5,603 | $45K | Form 4 |
| Jun 18, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 28,043 | $226K | Form 4 |
| Jun 17, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 5,399 | $44K | Form 4 |
| Jun 12, 2025 | Kaplan Matthew L. Director | Award | 30,000 | — | Form 4 |
| Jun 12, 2025 | Oliviero James F III Director | Award | 30,000 | — | Form 4 |
| Jun 12, 2025 | Hoberman Kenneth Director | Award | 30,000 | — | Form 4 |
| May 12, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 21,167 | $172K | Form 4 |
| May 8, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 2,400 | $21K | Form 4 |
| May 8, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 100 | $865 | Form 4 |
| May 8, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 100 | $865 | Form 4 |
| May 8, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 50 | $433 | Form 4 |
| May 7, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 9,614 | $83K | Form 4 |
| May 7, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 2,703 | $23K | Form 4 |
| May 6, 2025 | Mosseri Marlio Charles 10 percent owner | Purchase | 10,104 | $87K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 NVCT 内幕交易
NVCT 内幕交易
Nuvectis Pharma, Inc.（NVCT）内幕交易数据来源于公司内部人（包括Mosseri Marlio Charles (10 percent owner), BENTSUR RON (Chairman & CEO · Director), Sanchez Juan (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。NVCT内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Nuvectis Pharma, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
NVCT 内幕交易 · 5个问题Nuvectis Pharma, Inc.（NVCT）的内部人包括高管和董事，如Mosseri Marlio Charles (10 percent owner), BENTSUR RON (Chairman & CEO · Director), Sanchez Juan (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026